KRAS and non-small cell lung carcinoma: In particular, among KRAS mutated NSCLC, there are various subgroups already known to be different in terms of proteomic and transcriptomic profiles, as established by Skoulidis et al. [23], including the KRAS/LKB1 mutated patients that represent an intrinsically resistant group to anti-PD-1/PD-L1 immunotherapies, with low immune and inflammatory marker expression, and the KRAS-only mutated and KRAS/TP53 mutated patients that are more sensitive to single agent immunotherapy treatments.